Update on Urinary Tract Infection Antibiotic Resistance-A Retrospective Study in Females in Conjunction with Clinical Data
Overview
Authors
Affiliations
Urinary tract infections (UTIs) represent a frequent pathology among the female population that has become more and more difficult to treat in the past decade, considering the increase in antibiotic resistance-a serious global public health problem. A cross-sectional retrospective study was conducted for six months to report an update regarding the rates of resistance and susceptibility of uropathogens necessary for optimal treatment. A total of 5487 patients were screened, of which 524 (9.54%) were female patients who met the criteria for inclusion in the study. was the most common pathogen, representing 290 cases (55.34%), followed by spp. 82 (15.64%). presented the highest resistance to amoxicillin-clavulanic acid (R = 33.1%), followed by trimethoprim-sulfamethoxazole (R = 32.41%) and levofloxacin (R = 32.06%). The highest sensitivity rates were observed for fosfomycin (S = 96.55%), followed by imipenem (S = 93.1%). spp. showed the highest resistance to levofloxacin (R = 50.0%), followed by penicillin (R = 39.02%). The highest sensitivity was observed for fosfomycin (S = 90.24%), linezolid (S = 89.02%), and nitrofurantoin (S = 86.58%). The second most frequent Gram-negative uropathogen was represented by spp., which had the highest resistance to amoxicillin-clavulanic acid (R = 35.89%), followed by levofloxacin (R = 25.64) and trimethoprim-suflamethoxazole (R = 24.35%). The most frequently associated pathology was an episode of UTI in the previous year, followed by diabetes and chronic kidney disease. Antibiotic resistance is a serious problem for all clinicians who treat UTIs. An up-to-date knowledge of antibiotic resistance rates is a major necessity to stop its evolution. Overall, the highest resistance rates were observed for aminopenicillins, fluoroquinolones, and trimethoprim-sulfamethoxazole. The best susceptibility rates were observed for fosfomycin, nitrofurantoin, and carbapenems. Our report aims to guide clinicians whenever they are forced to prescribe antibiotics empirically.
Cipriani C, Carilli M, Rizzo M, Miele M, Sinibaldi-Vallebona P, Matteucci C Antibiotics (Basel). 2025; 14(2).
PMID: 40001388 PMC: 11851568. DOI: 10.3390/antibiotics14020144.
Johny V F, Menon V, Georgy S, Saju C, Jini M BMC Infect Dis. 2025; 25(1):276.
PMID: 40000942 PMC: 11863663. DOI: 10.1186/s12879-025-10634-x.
Epidemiology of urinary tract infections in the Middle East and North Africa, 1990-2021.
Amiri F, Safiri S, Aletaha R, Sullman M, Hassanzadeh K, Kolahi A Trop Med Health. 2025; 53(1):16.
PMID: 39910666 PMC: 11796260. DOI: 10.1186/s41182-025-00692-x.
Deleanu I, Grosu E, Ficai A, Ditu L, Motelica L, Oprea O Polymers (Basel). 2024; 16(21).
PMID: 39518238 PMC: 11548089. DOI: 10.3390/polym16213028.